Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69610 | 0.67 | AKT1 (0.40) | ALDH1A1MAPTMEN1KMT2AALOX15 | |
| SCHEMBL450165 | 0.67 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL8183045 | 0.67 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL2565902 | 0.65 | ALDH1A1 (0.42) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL4452760 | 0.65 | CYP1A2 (0.33) | NPC1RAB9A | |
| SCHEMBL1706140 | 0.65 | LTA4H (0.35) | — | |
| SCHEMBL1799678 | 0.65 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL630904 | 0.64 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL5757952 | 0.63 | GAA (0.45) | ALDH1A1HPGDMAPTHSD17B10MEN1 | |
| SCHEMBL569614 | 0.63 | PDE10A (0.45) | ALDH1A1KDM4EHPGDMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | claimed |
| CN-106456609-A | Substituted indazole compounds as irak4 inhibitors | 奥瑞基尼探索技术有限公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | claimed |
| EP-1751090-B1 | ACID DERIVATIVES OF SUBSTITUTED CYCLOHEXYL-1,4-DIAMINES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | claimed |
| EP-2276764-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | claimed |
| US-8178523-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-15 | — | — | US | claimed |
| US-20110020275-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| EP-2276764-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009120745-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | claimed |
| US-7365077-B2 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-29 | — | — | US | claimed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| EP-2699562-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20190151330-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2019-05-23 | — | — | US | disclosed |
| US-20110020275-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2276764-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120745-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | disclosed |
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | ALDH1A1 2808/4885KDM4E 2957/4885HPGD 623/4885 |
| US-20090099239-A1 | Antiviral Compounds and Methods | MAVS, ZC3HAV1, EIF2AK2 | ALDH1A1 3086/4885KDM4E 2925/4885HPGD 2986/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | ALDH1A1 1493/4885KDM4E 2541/4885HPGD 754/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | ALDH1A1 1493/4885KDM4E 2541/4885HPGD 754/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | ALDH1A1 1493/4885KDM4E 2541/4885HPGD 754/4885 |
| US-20110020275-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ALDH1A1 220/4885KDM4E 4322/4885HPGD 1448/4885 |
| US-20190151330-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | ALDH1A1 142/4885KDM4E 3418/4885HPGD 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.